ArticleCancer research communications2025
Adiposity Status Close to Diagnosis and Its Association with Prostate Cancer Survival in the UK Biobank.
Article in Cancer research communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Substantial evidence links higher adiposity to prostate cancer development. The relationship between adiposity and outcomes after a prostate cancer diagnosis, however, is unclear. This study aimed to investigate the association between adiposity measured close to prostate cancer diagnosis and all-cause and prostate cancer-specific mortality in a prospective cohort study. Cox regression analyses estimated HRs and 95% confidence intervals (CI) for mortality in 3,760 men in the UK Biobank who had first primary prostate cancer and complete data on body mass index (BMI), waist circumference, hip circumference, waist-to-hip ratio (measured up to 2 years before or up to 5 years after diagnosis), and on covariates (diagnosis age and year, smoking, Townsend deprivation index, exercise, sedentary activities, and alcohol). The waist-to-height ratio and body fat percentage (assessed by bioelectrical impedance) were also evaluated as adiposity measures. Each 5-U increment in pre- or post-diagnosis BMI (N = 3,760) was associated with a 30% (95% CI, 1.18-1.44) higher rate of all-cause mortality (deaths = 680), a 33% (95% CI, 1.15-1.52) higher rate of prostate cancer-specific mortality (deaths = 331), and a 28% (95% CI, 1.12-1.47) higher rate of non-prostate cancer mortality (deaths = 347). Positive associations of similar magnitude were observed for separate analyses by pre- and post-diagnosis BMI and for waist and hip circumference, waist-to-hip ratio, waist-to-height ratio, and body fat percentage. Obesity assessed close to prostate cancer diagnosis is associated with higher mortality. More studies are needed to strengthen the evidence and clarify the mechanisms behind the observed associations. SIGNIFICANCE: Patients with prostate cancer might improve their chances of survival by avoiding obesity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.